In myeloma-resistant T cell receptor (TCR)-transgenic severe combined immunodeficiency (SCID) mice [182] injected with myeloma cells, in vivo neutralization of IL-1 resulted in a decreased production of IFN-γ by tumor-specific Th1 cells and attenuated infiltration of macrophages and tumor growth [183]. Here, IL1B is linked to plasma cell myeloma.